Targeted therapies for hormone-refractory prostate cancer / 中华男科学杂志
National Journal of Andrology
;
(12): 1108-1112, 2010.
Article
in Chinese
| WPRIM
| ID: wpr-266227
ABSTRACT
Prostate cancer is one of the most common type of cancer among men after middle age. Androgen withdrawal can delay its progression in the initial stage, but it finally becomes independent of androgens in almost all the cases. The combination of docetaxel with prednisone is currently a standard first-line treatment for patients with hormone-refractory prostate cancer (HRPC), but hitherto there is no established second-line therapy. In view of the molecular pathogenesis of HRPC, this article presents an overview on several promising drugs that target specific pathways, involving angiogenesis, cell signaling, apoptosis and proliferation, and immune modulation, either as single agents or in combination with cytotoxic chemotherapy.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pharmacology
/
Prostatic Neoplasms
/
Drug Resistance, Neoplasm
/
Drug Therapy
/
Hormones
Limits:
Humans
/
Male
Language:
Chinese
Journal:
National Journal of Andrology
Year:
2010
Type:
Article
Similar
MEDLINE
...
LILACS
LIS